Evidence map›Paper›PMID 41881999›Full record

ReviewNPJ vaccines2026

Cancer vaccines and RNA therapeutics: exploring the impact of microRNAs.

Miriam Valeria Rojas-Rojas, Ainhoa Muiños-García, Cristian Arriaga-Canon, Luis Alonso Herrera

Abstract readReview
In one paragraph

Review in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Miriam Valeria Rojas-RojasLaboratorio de Innovación y Medicina de Precisión, Núcleo A, Instituto Nacional de Medicina Genómica, Ciudad de México, México.
Ainhoa Muiños-GarcíaLaboratorio de Innovación y Medicina de Precisión, Núcleo A, Instituto Nacional de Medicina Genómica, Ciudad de México, México.
Cristian Arriaga-CanonLaboratorio de Innovación y Medicina de Precisión, Núcleo A, Instituto Nacional de Medicina Genómica, Ciudad de México, México. cgarriaga@inmegen.gob.mx.
Luis Alonso HerreraEscuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Ciudad de México, México. lherreram@tec.mx.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA-based therapies have been studied for decades, gaining global recognition with the success of the Pfizer-BioNTech mRNA vaccine. Despite ongoing challenges in standardization and optimization, RNA therapeutics have become central to precision medicine. This success has driven interest in oncology applications, particularly microRNAs (miRNAs), which regulate gene expression and cancer-related processes. This article reviews RNA-based cancer therapies, highlighting miRNA potential and clinical translation challenges.

Identifiers

PMID41881999
PMCPMC13181097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.